

Francesco Leone

List of Publications by Citations

Source: <https://exaly.com/author-pdf/202101/francesco-leone-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

2,901
citations

25
h-index

51
g-index

112
ext. papers

3,532
ext. citations

5
avg. IF

4.4
L-index

#	Paper	IF	Citations
103	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 738-746	21.7	533
102	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91	9.8	144
101	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 1680-5	12.9	136
100	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naïve patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2014 , 25, 1750-1755	10.3	131
99	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. <i>BMC Cancer</i> , 2010 , 10, 631	4.8	128
98	Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. <i>Gastroenterology</i> , 1997 , 113, 567-72	13.3	128
97	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). <i>Cancer</i> , 2016 , 122, 574-81	6.4	96
96	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 34, 148-162.e7	24.3	77
95	Predicting locally advanced rectal cancer response to neoadjuvant therapy with F-FDG PET and MRI radiomics features. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 878-888	8.8	73
94	Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. <i>Cancer</i> , 2013 , 119, 277-84	6.4	65
93	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014 , 25, 1373-1378	10.3	61
92	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. <i>Digestive and Liver Disease</i> , 2016 , 48, 231-41	3.3	60
91	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014 , 110, 2165-9	8.7	56
90	The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. <i>Oncologist</i> , 2012 , 17, 1430-8	5.7	55
89	AURORAL RADIO EMISSION FROM STARS: THE CASE OF CU VIRGINIS. <i>Astrophysical Journal Letters</i> , 2011 , 739, L10	7.9	46
88	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1395-1402	5.7	45
87	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020 , 25, 481-487	5.7	43

86	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 156	12.8	40
85	Epidemiological and virological analysis of couples infected with hepatitis C virus. <i>Gut</i> , 1999 , 45, 112-6	19.2	39
84	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020 , 5, e000911	6	35
83	Biliary tract carcinomas: from chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 136-48	7	33
82	Fluoropyrimidine-induced cardiotoxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 124, 1-10	7	30
81	NON-DETECTION OF MAGNETIC FIELDS IN THE CENTRAL STARS OF THE PLANETARY NEBULAE NGC 1360 AND LSS 1362. <i>Astrophysical Journal Letters</i> , 2011 , 731, L33	7.9	30
80	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
79	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. <i>BMC Cancer</i> , 2016 , 16, 90	4.8	26
78	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
77	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020 , 40, 704-711	7.9	25
76	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
75	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 326-35	4.7	24
74	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. <i>International Journal of Cancer</i> , 2018 , 143, 907-920	7.5	23
73	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. <i>Tumor Biology</i> , 2016 , 37, 4041-52	2.9	23
72	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , 2013 , 119, 3429-35	6.4	23
71	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3508-3508	2.2	23
70	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 256-262.e2	3.8	22
69	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017 , 83, 106-115	7.5	21

68	Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 1033-40	5	21
67	Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach. <i>Diseases of the Colon and Rectum</i> , 2006 , 49, 1596-601	3.1	21
66	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016 , 7, 69060-69074	3.3	21
65	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 115, 1-12	7	20
64	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016 , 21, 600-7	5.7	20
63	Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to evaluate the outcome of a web-based stepped care intervention. <i>BMC Cancer</i> , 2010 , 10, 361	4.8	19
62	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
61	Linifanib: current status and future potential in cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 677-87	3.5	16
60	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS774-TPS774	2.2	16
59	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000403	6	15
58	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2003 , 74, 593-601	6.5	15
57	Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. <i>Bone Marrow Transplantation</i> , 2001 , 27, 517-23	4.4	15
56	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. <i>Cancers</i> , 2019 , 11,	6.6	14
55	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e457-e470	3.8	14
54	Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1528-38	6.1	13
53	Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. <i>Oncotarget</i> , 2016 , 7, 52354-52363	3.3	13
52	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016 , 11, 593-603	5	12
51	Emerging molecular target antagonists for the treatment of biliary tract cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 63-75	3.7	11

50	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016 , 14, 119	8.5	11
49	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. <i>BMC Genomics</i> , 2018 , 19, 440	4.5	10
48	Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 218-26	7	10
47	Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. <i>Journal of Hepatology</i> , 1998 , 29, 689-94	13.4	10
46	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102877	7	9
45	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018 , 95, 344-352	3.6	9
44	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
43	A Method to Measure the Transverse Magnetic Field and Orient the Rotational Axis of Stars. <i>Astrophysical Journal</i> , 2017 , 848, 107	4.7	8
42	Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. <i>Oncotarget</i> , 2016 , 7, 86766-86780	3.3	8
41	Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 109-14	3.5	8
40	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2121-2137	4	7
39	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e394-e401	3.8	7
38	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. <i>Cancers</i> , 2019 , 11,	6.6	7
37	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. <i>Anti-Cancer Drugs</i> , 2008 , 19, 689-96	2.4	7
36	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3648-TPS3648	2.2	7
35	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , 2020 , 147, 3215-3223	7.5	7
34	ZEEMAN DOPPLER MAPS: ALWAYS UNIQUE, NEVER SPURIOUS?. <i>Astrophysical Journal</i> , 2017 , 834, 24	4.7	6
33	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. <i>BMC Cancer</i> , 2016 , 16, 793	4.8	6

32	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. <i>BMC Cancer</i> , 2014 , 14, 918	4.8	6
31	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3506-3506	2.2	6
30	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. <i>PLoS ONE</i> , 2018 , 13, e0191593	3.7	6
29	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015 , 8, 1149-56	4.4	5
28	Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1145; author reply 1145-6	2.2	5
27	Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 68-74	4.7	5
26	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. <i>Cancers</i> , 2021 , 13,	6.6	4
25	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 591-597	3.6	4
24	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	4
23	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. <i>Cancers</i> , 2019 , 11,	6.6	3
22	Assessment of a High Sensitivity Method for Identification of R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. <i>Cancers</i> , 2019 , 11,	6.6	3
21	SHARK (System for coronagraphy with High order Adaptive optics from R to K band): a proposal for the LBT 2nd generation instrumentation 2014 ,		3
20	Targeted agents: how can we improve the outcome in biliary tract cancer?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013 , 2, 31-3	2.1	3
19	"Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 133, 17-24	7	3
18	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018 , 12, 33-37	4.5	2
17	The first Second solar spectrum ever observed in a star different than the sun: A high-resolution spectropolarimetric Atlas of 89 Herculis. <i>Astronomische Nachrichten</i> , 2019 , 340, 409-412	0.7	2
16	A polarimetric unit for HARPS-North at the Telescopio Nazionale Galileo: HANPO 2014 ,		2
15	Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2017 , 28, vi7	10.3	2

14	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014 , 25, 2443-2444	10.3	2
13	The HARPS-North@TNG polarimeter 2016 ,		2
12	SIFAP2: a new versatile configuration at the TNG for the MPPC based photometer 2018 ,		2
11	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1451-1463	4	2
10	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021 , 60, 1317-1324	3.2	2
9	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. <i>Chronobiology International</i> , 2015 , 32, 1359-66	3.6	1
8	Liver Metastases in Colon Cancer 2012 , 77-91		1
7	Postoperative nomogram for predicting survival after resection for intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4129-4129	2.2	1
6	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 771418	5.3	1
5	Discovery of Ground-state Absorption Line Polarization and Sub-Gauss Magnetic Field in the Post-AGB Binary System 89 Her. <i>Astrophysical Journal Letters</i> , 2020 , 902, L7	7.9	0
4	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2021 , 1-10	2.3	0
3	Improvement of metastatic colorectal cancer patient survival: Single institution experience.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15633-e15633	2.2	
2	Adjuvant Chemotherapy and Follow-Up. <i>Updates in Surgery Series</i> , 2011 , 153-158	0.1	
1	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	